头孢地尼和头孢克洛治疗社区获得性轻中度细菌性肺炎的对照研究

目的　评价头孢地尼治疗社区获得性轻、中度细菌性肺炎的有效性与安全性。方法　采用前瞻性随机单盲平行对照临床试验 ,比较头孢地尼和头孢克洛在治疗社区获得性轻、中度细菌性肺炎的临床和细菌学效果及不良反应。用头孢地尼治疗社区获得性肺炎 33例 (头孢地尼组 ) ,予头孢地尼每次 10 0mg,口服 ,每日 3次 ;以头孢克洛治疗 31例作为对照药物 (头孢克洛组 ) ,予头孢克洛每次 5 0 0mg ,口服 ,每日 3次。两组疗程均为 7～ 14d。结果　头孢地尼组与头孢克洛组的临床痊愈率分别为 84 8%和 77 4 % ,有效率分别为 93 9%和 87 1% ,细菌阳性率分别为 81 8%和 80 7% ,细菌清除率分别为 96 3%和 88 0 % ,不良反应发生率分别 3%和 6 5 % ,以上结果经统计学处理 ,两组差异均无显著意义 (P >0 0 5 )。头孢地尼组与头孢克洛组的平均用药时间分别为 10 8± 1 6d和 12 1± 1 7d ,两组比较 ,具有高度显著性差异 (P <0 0 1)。结论　头孢地尼治疗社区获得性轻、中度细菌性肺炎安全、有效并可缩短疗程

Comparative study on cefdinir and cefaclor in the treatment of patients with mild to moderate bacterial community acquired pneumonia

OBJECTIVE: To evaluate the efficacy and safety of cefdinir in the treatment of patients with mild to moderate bacterial community acquired pneumonia (CAP). METHODS: A prospective single-blind randomized controlled clinical study was performed comparing cefdinir with cefaclor in the treatment of sixty-four patients with CAP. The clinical and bacteriological efficacy and safety were compared between cefdinir and cefaclor in treating mild to moderate CAP. Thirty-three patients were treated with cefdinir 100 mg, orally, three times a day (cefdinir group), thirty-one patients were treated with cefaclor 500 mg, orally, three times a day (cefaclor group). In both groups 7-14 d was a treatment course. RESULTS: The cure rate of cefdinir and cefaclor was 84.8% and 77.4% respectively and the overall efficacy rate was 93.9% and 87.1% respectively. The bacterial positive rates and bacterial eradication rates of the two groups were 81.8%, 80.7% and 96.3%, 88%, respectively. The adverse drug reaction rate were 3% in cefdinir group and 6.5% in cefaclor group. There was no statistical significant difference between the two groups for the above results (P >0.05). The time of given medicine of cefdinir and cefaclor was (10.8 +/- 1.6) d and (12.1 +/- 1.7) d (P <0.01) respectively. CONCLUSION: cefdinir is safe and effective, shorten the course of treatment in the treatment of mild to moderate bacterial community acquired pneumonia.